Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Given Average Rating of “Hold” by Brokerages

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) has earned a consensus rating of “Hold” from the six ratings firms that are currently covering the stock, MarketBeat.com reports. Four analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $9.40.

Several equities research analysts have issued reports on RXRX shares. Needham & Company LLC decreased their price objective on shares of Recursion Pharmaceuticals from $16.00 to $11.00 and set a “buy” rating for the company in a research note on Wednesday, September 4th. KeyCorp decreased their price objective on shares of Recursion Pharmaceuticals from $16.00 to $12.00 and set an “overweight” rating for the company in a research note on Thursday, July 11th. Leerink Partners decreased their price objective on shares of Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating for the company in a research note on Tuesday, September 3rd. Finally, Jefferies Financial Group decreased their price objective on shares of Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating for the company in a research note on Tuesday, September 3rd.

Recursion Pharmaceuticals Price Performance

Recursion Pharmaceuticals stock opened at $6.12 on Tuesday. Recursion Pharmaceuticals has a 1 year low of $4.97 and a 1 year high of $15.74. The firm has a 50 day moving average price of $7.30 and a 200 day moving average price of $8.74. The company has a market cap of $1.72 billion, a price-to-earnings ratio of -3.82 and a beta of 0.82. The company has a debt-to-equity ratio of 0.04, a quick ratio of 6.07 and a current ratio of 6.07.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its earnings results on Thursday, August 8th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.05). Recursion Pharmaceuticals had a negative net margin of 755.37% and a negative return on equity of 79.47%. The company had revenue of $14.42 million during the quarter, compared to analysts’ expectations of $11.96 million. During the same quarter in the previous year, the firm posted ($0.38) earnings per share. Recursion Pharmaceuticals’s revenue for the quarter was up 30.9% compared to the same quarter last year. Sell-side analysts predict that Recursion Pharmaceuticals will post -1.58 earnings per share for the current year.

Insider Activity

In other news, CEO Christopher Gibson sold 20,000 shares of the company’s stock in a transaction on Wednesday, September 4th. The shares were sold at an average price of $6.04, for a total value of $120,800.00. Following the completion of the transaction, the chief executive officer now directly owns 762,656 shares in the company, valued at $4,606,442.24. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, COO Tina Marriott sold 6,000 shares of the company’s stock in a transaction on Thursday, June 27th. The shares were sold at an average price of $7.21, for a total value of $43,260.00. Following the sale, the chief operating officer now directly owns 535,457 shares of the company’s stock, valued at $3,860,644.97. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Christopher Gibson sold 20,000 shares of the company’s stock in a transaction on Wednesday, September 4th. The shares were sold at an average price of $6.04, for a total transaction of $120,800.00. Following the completion of the sale, the chief executive officer now directly owns 762,656 shares in the company, valued at $4,606,442.24. The disclosure for this sale can be found here. Over the last three months, insiders sold 231,682 shares of company stock worth $1,711,117. 15.75% of the stock is currently owned by company insiders.

Institutional Trading of Recursion Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in the stock. Ghisallo Capital Management LLC acquired a new stake in Recursion Pharmaceuticals in the second quarter valued at $8,250,000. Perceptive Advisors LLC acquired a new stake in Recursion Pharmaceuticals in the second quarter valued at $5,769,000. Algert Global LLC acquired a new stake in Recursion Pharmaceuticals in the second quarter valued at $129,000. Scientech Research LLC acquired a new stake in Recursion Pharmaceuticals in the second quarter valued at $1,052,000. Finally, The Manufacturers Life Insurance Company raised its holdings in shares of Recursion Pharmaceuticals by 32.6% during the second quarter. The Manufacturers Life Insurance Company now owns 111,613 shares of the company’s stock worth $837,000 after purchasing an additional 27,440 shares during the period. 89.06% of the stock is owned by institutional investors and hedge funds.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.